RBC Capital Downgrades Intercept Pharmaceuticals (ICPT) to Sector Perform

RBC Capital analyst Brian Abrahams downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Outperform to Sector Perform with a price target of $115.00.

Abrahams cites the valuation for the downgrade along with fewer NT catalysts. The analyst would view any pullback from the current level as an opportunity to add to positions.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $111.65 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades Rakuten Inc. (4755:JP) (RKUNF) to Neutral
• PBF Energy (PBF) PT Raised to $57 at Mizuho
• Intuitive Surgical (ISRG) PT Lowered to $520 at TD Cowen